Insilico Partners With US Firm to Build AI Longevity Model as Stock Doubles Since IPO
Updated
Updated · Bloomberg · May 26
Insilico Partners With US Firm to Build AI Longevity Model as Stock Doubles Since IPO
5 articles · Updated · Bloomberg · May 26
Insilico Medicine is working with closely held Human Life Foundation Models Inc. to develop what the companies expect will be among the first AI foundation models focused on human longevity science.
The model is designed to spot disease risks earlier and speed the discovery of therapies, extending Insilico's use of AI beyond drug discovery into longevity research.
Insilico's shares have doubled since the Hong Kong AI drug discovery firm's December market debut, giving the partnership added visibility as it expands into a new research area.
Insilico's AI-designed drugs are now in human trials. How can we trust therapies born from an unexplainable 'black box'?
AI promises a cure for aging using our personal data. What is the ultimate cost for this digital fountain of youth?